Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calcium antagonists. Their physiological differences.

E D Frohlich1

  • 1Alton Ochsner Medical Foundation, New Orleans, LA 70121.

American Journal of Hypertension
|July 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventive cardiology: more than just lipid lowering.

Preventive cardiology·2002
Same author

Profiles in cardiology. Harriet P. Dustan.

Clinical cardiology·2002
Same author

Sixtieth anniversary of Angiotensin.

Hypertension (Dallas, Tex. : 1979)·2001
Same author

Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats.

Hypertension (Dallas, Tex. : 1979)·2001
Same author

Local hemodynamic changes in hypertension: insights for therapeutic preservation of target organs.

Hypertension (Dallas, Tex. : 1979)·2001
Same author

Isolated systolic hypertension in elderly WKY is reversed with L-arginine and ACE inhibition.

Hypertension (Dallas, Tex. : 1979)·2001
Same journal

ADAM17 as a promising molecular target for organ protection in antihypertensive therapy.

American journal of hypertension·2026
Same journal

Efficacy and Safety of Baxdrostat in the Management of Uncontrolled Hypertension: A Systematic Review and Meta-Analysis.

American journal of hypertension·2026
Same journal

Hemodynamic Evolution of Heart Failure from Hypertension: Lower Stroke Volume Index and Higher Heart Rate.

American journal of hypertension·2026
Same journal

Opposite Seasonal Variation in Nighttime and Morning Blood Pressure: A Longitudinal Study of Patients with Hypertension.

American journal of hypertension·2026
Same journal

Screening for Postprandial Hypotension: The Importance of Home Blood Pressure Monitoring.

American journal of hypertension·2026
Same journal

Distinct Mediating Roles of Hypertension in Arterial Stiffness Mechanisms Associated with Cardiovascular Disease Risk: A Community-Based Cohort Study.

American journal of hypertension·2026
See all related articles

Calcium channel blockers exhibit significant differences in cardiovascular and renal effects, contrary to common assumptions of similarity. Understanding these distinct actions is crucial for effective hypertension and nephropathy treatment.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Calcium channel blockers are often perceived as clinically and physiologically similar.
  • However, significant structural, chemical, and pharmacological heterogeneity exists among these agents.

Purpose of the Study:

  • To explore the distinct cardiovascular and renal effects of various calcium channel blockers.
  • To highlight the heterogeneity of calcium channel blockers beyond their vasodilating and hypotensive capabilities.

Main Methods:

  • Review of existing literature on the cardiovascular and renal effects of calcium channel blockers.
  • Comparative analysis of pharmacological actions, including chronotropic, inotropic, and vascular resistance effects.
  • Examination of effects on cardiac and renal mass, blood flow, and pressure.

Related Experiment Videos

Main Results:

  • Not all calcium channel blockers possess potent antihypertensive effects; nimodipine, for instance, is a cerebrovascular vasodilator.
  • Agents vary in cardiac effects: verapamil has strong negative chronotropic/inotropic actions, nifedipine has minimal, and diltiazem is moderate.
  • Some calcium channel blockers increase right ventricular mass alongside left ventricular mass reduction.
  • Certain agents (diltiazem, nitrendipine, clindiazem) increase renal blood flow and decrease glomerular pressure, potentially reducing proteinuria.

Conclusions:

  • Calcium channel blockers display greater physiological and clinical heterogeneity than other antihypertensive drug classes.
  • These diverse effects suggest potential therapeutic applications in reversing hypertensive and diabetic nephropathy.
  • Tailoring calcium channel blocker selection based on specific cardiovascular and renal profiles is essential for optimal patient outcomes.